Liesbeth Bergman

1.1k total citations
10 papers, 802 citations indexed

About

Liesbeth Bergman is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Liesbeth Bergman has authored 10 papers receiving a total of 802 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Liesbeth Bergman's work include Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (4 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Liesbeth Bergman is often cited by papers focused on Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (4 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Liesbeth Bergman collaborates with scholars based in Netherlands and United States. Liesbeth Bergman's co-authors include Flora E. van Leeuwen, M.P.W. Gallee, Harry Hollema, J. Benraadt, M. Limburg, Jan van der Meulen, J. Dik F. Habbema, J.A. van Dongen, Frits S.A.M. van Dam and Hans Peterse and has published in prestigious journals such as The Lancet, Cancer and Stroke.

In The Last Decade

Liesbeth Bergman

9 papers receiving 766 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liesbeth Bergman Netherlands	7	311	302	239	195	142	10	802
Rayna K. Matsuno United States	19	383 1.2×	169 0.6×	227 0.9×	137 0.7×	43 0.3×	29	865
H. B. Muss United States	13	380 1.2×	193 0.6×	200 0.8×	67 0.3×	55 0.4×	28	636
Charles H. F. Gimbrère Netherlands	7	214 0.7×	369 1.2×	125 0.5×	203 1.0×	98 0.7×	8	719
C Mettlin United States	17	496 1.6×	149 0.5×	181 0.8×	74 0.4×	95 0.7×	39	1.3k
Sheryl L. Silfen United States	14	318 1.0×	442 1.5×	149 0.6×	190 1.0×	19 0.1×	25	994
D B Thomas United States	11	336 1.1×	190 0.6×	100 0.4×	74 0.4×	94 0.7×	17	731
Lars‐Erik Rutqvist Sweden	18	788 2.5×	296 1.0×	194 0.8×	31 0.2×	84 0.6×	25	1.2k
A. Gudgeon South Africa	12	593 1.9×	476 1.6×	379 1.6×	46 0.2×	59 0.4×	21	973
Peggy Wan United States	15	377 1.2×	325 1.1×	140 0.6×	72 0.4×	50 0.4×	22	971
T M Mack United States	4	139 0.4×	215 0.7×	61 0.3×	43 0.2×	172 1.2×	6	697

Countries citing papers authored by Liesbeth Bergman

Since Specialization

Citations

This map shows the geographic impact of Liesbeth Bergman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liesbeth Bergman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liesbeth Bergman more than expected).

Fields of papers citing papers by Liesbeth Bergman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liesbeth Bergman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liesbeth Bergman. The network helps show where Liesbeth Bergman may publish in the future.

Co-authorship network of co-authors of Liesbeth Bergman

This figure shows the co-authorship network connecting the top 25 collaborators of Liesbeth Bergman. A scholar is included among the top collaborators of Liesbeth Bergman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liesbeth Bergman. Liesbeth Bergman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Bergman, Liesbeth, et al.. (2001). Tamoxifen and risk of endometrial cancer - Reply. University of Groningen research database (University of Groningen / Centre for Information Technology). 357(9249). 67–67. 1 indexed citations

2.

Leeuwen, Flora E. van, et al.. (2001). Tamoxifen and risk of endometrial cancer. The Lancet. 357(9249). 67–67. 6 indexed citations

3.

Bergman, Liesbeth, et al.. (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. The Lancet. 356(9233). 881–887. 388 indexed citations

4.

Leeuwen, Flora E. van, Liesbeth Bergman, & J. Benraadt. (1998). IV.2 Does risk of endometrial cancer increase with longer duration of tamoxifen use?. European Journal of Cancer. 34. S44–S45. 4 indexed citations

5.

Bergman, Liesbeth. (1996). Tamoxifen, balancing risks and benefits. The Netherlands Journal of Medicine. 49(6). 228–234.

6.

Bergman, Liesbeth, J.A. van Dongen, B van Ooijen, & Flora E. van Leeuwen. (1995). Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease?. Breast Cancer Research and Treatment. 34(1). 77–83. 42 indexed citations

7.

Bergman, Liesbeth, Jan van der Meulen, M. Limburg, & J. Dik F. Habbema. (1995). Costs of Medical Care After First-Ever Stroke in the Netherlands. Stroke. 26(10). 1830–1836. 126 indexed citations

8.

Bergman, Liesbeth, Huub M. Kluck, F.E. van Leeuwen, et al.. (1992). The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: A population-based study. European Journal of Cancer. 28(8-9). 1475–1480. 70 indexed citations

9.

Bergman, Liesbeth, et al.. (1991). Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. Breast Cancer Research and Treatment. 18(3). 189–198. 73 indexed citations

10.

Bergman, Liesbeth, et al.. (1991). The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer. 67(9). 2227–2234. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact